市售天山堇菜药材质量评价研究

目的 补充提高维药天山堇菜药材质量标准。方法 采用生药鉴别方法对市售天山堇菜药材进行性状特征、显微特征及薄层色谱定性鉴别;采用Agilent TC-C₁₈色谱柱（4.6 mm×150 mm,5 μm）;流动相为乙腈-0.1%磷酸水溶液（15：85）;柱温35℃,检测波长349 nm,流速0.8 mL·min^-1,对天山堇菜药材中秦皮乙素含量进行测定。采用中国药典2015年版一部附录项下方法对天山堇菜中醇溶性浸出物、水分、总灰分和酸不溶性灰分进行测定。结果 对天山堇菜药材性状特征、显微特征进行了专属描述确定;10批市售天山堇菜药材进行了薄层定性鉴别;活性成分秦皮乙素在0.1~3.0 μg·mL^-1（r=0.999 3）内呈良好的线性关系,平均回收率为98.56%（RSD=1.90%）。确定了天山堇菜中秦皮乙素、醇溶性浸出物、水分、总灰分和酸不溶性灰分的检查限度。结论 补充提高建立的维药天山堇菜质量控制方法简便、准确、稳定,可以用于天山堇菜药材的质量控制。     

Heterogeneity of human serum high-density lipoprotein (HDL 2 )

A technique is described for the detection of free fatty acids, triglycerides, wax esters and cholesterol esters on thin-layer Chromatographic plates. The fatty acids present in each fraction can be recovered from the plates after detection and quantitatively measured by gas-liquid chiomatography. This procedure has been sucessfully applied to the analysis of skin surface lipids.     

Biological lung volume reduction: a new bronchoscopic therapy for advanced emphysema

BACKGROUND: Biological lung volume reduction (BLVR) using biological reagents to remodel and shrink damaged regions of lung has previously been accomplished in sheep with experimental pulmonary emphysema. This report summarizes the initial clinical experience including a 3-month follow-up using this technique in humans. METHODS: An open-label phase 1 trial designed to evaluate the safety of BLVR in patients with advanced heterogeneous emphysema enrolled six patients. Of these, three patients received unilateral treatment at two pulmonary subsegments (group 1) and three patients received unilateral treatment at four pulmonary subsegments (group 2). The incidence of adverse events and changes in pulmonary function test results, symptoms, and exercise capacity were evaluated. RESULTS: The mean (+/- SD) age of the six men enrolled in the study was 66 +/- 5.7 years (age range, 57 to 73 years). BLVR was well tolerated in both treatment groups and was not associated with any serious complications. All patients were discharged from the hospital on posttreatment day 1. Although the primary purpose of the study was to examine safety, improvements were observed in mean vital capacity (+7.2 +/- 9.5%; range, -2% to + 19%), mean residual volume (RV) [-7.8 +/- 8.5%; range, + 1% to -22%], mean RV/total lung capacity ratio (-6.6 +/- 4.7%; range, -1% to -15%), mean 6-min walk distance (+14.5 +/- 18.5%; range, 0 to + 51%), and in mean dyspnea score. On average, group 2 patients experienced greater benefit from BLVR than group 1 patients, suggesting a dose-response pattern. CONCLUSIONS: Preliminary results indicate that BLVR can be safe and may produce benefits in appropriately selected patients with advanced heterogeneous emphysema.     

Prevalence and reversibility of pulmonary dysfunction in refractory systemic lupus: improvement correlates with disease remission following hematopoietic stem cell transplantation

AIM: To report the prevalence and reversibility of pulmonary function test (PFT) abnormalities among systemic lupus erythematosus (SLE) patients, refractory to therapy, undergoing hematopoietic stem cell transplantation (HSCT). METHODS: Thirty-four SLE patients received 200 mg/kg cyclophosphamide and 90 mg/kg equine antithymocyte globulin followed by HSCT. PFTs were performed prior to, at 6 months, and yearly following HSCT. RESULTS: The prevalence of significant PFT abnormalities was high (97%). Low FEV(1) and FVC occurred in 26 of 34 patients (76%). A significant abnormality in diffusion capacity of the lung for carbon monoxide (Dlco) occurred in 26 of 32 individuals able to complete Dlco testing (81%). Dlco 18 months after HSCT. Five of 28 patients had a normal entry FVC; for each, the FVC remains normal. Of the 23 patients with an abnormal baseline FVC, 18 have improved, 15 completely and 3 partially. Eight of these 18 patients also have improved Dlco. The two patients with a diagnosis of SLS and one patient with SLE-related pulmonary hypertension improved in both parameters. Only 5 of 23 patients with an abnormal FVC did not improve. Each of these five patients retained active lupus in spite of HSCT. CONCLUSION: The prevalence of lung impairment among SLE patients requiring long-term immune suppression is high. Following HSCT, pulmonary impairments can improve, which is sustained if disease control is sustained.     

疏血通脉胶囊定性定量方法研究

目的建立疏血通脉胶囊定性定量研究方法。方法采用TLC法对制剂中的薤白、瓜蒌皮、冰片进行鉴别,采用HPLC法,对制剂中的人参皂苷Rg1、人参皂苷Rb1和三七皂苷R1进行含量测定。结果 TLC法可检出薤白、瓜蒌皮、冰片。人参皂苷Rg1、人参皂苷Rb1和三七皂苷R1的线性范围分别为0.102¹.020、0.0951.020、0.095⁰.950和0.0350.950和0.035⁰.350 mg·mL-1(r=0.999 9),平均回收率分别为98.9%、99.6%和100.4%,RSD分别为2.0%、1.7%和1.7%(n=6)。结论该方法操作简单可靠,专属性强,可用于控制疏血通脉胶囊的质量。     

伤痛康胶囊的制备与质量控制

目的：研究伤痛康胶囊的制备工艺及鉴别方法。方法：采用正交设计实验优选最佳水提工艺,采用显微鉴别、薄层鉴别法对制剂进行质量控制。结果：该制剂最佳水提工艺为加8倍量水,提取3次,每次提取时间为2小时。制剂按照鉴别方法均可检出。结论：该制备工艺及制剂鉴别方法合理可行,专属性、重现性良好。     

藏药八味獐牙菜丸的质量标准研究

目的：建立测定藏药八味獐牙菜丸中盐酸小檗碱含量的方法。方法：采用薄层色谱法和高效液相色谱法。结果：建立了八味獐牙菜丸中兔耳草和小檗皮的薄层色谱鉴别方法,并采用HPLC测定了该藏药制剂中小檗皮的有效成分盐酸小檗碱的含量,其回归方程为：y=4629102.46x-136034.70,r=0.9995,盐酸小檗碱的平均回收率为97.30%,RSD=1.57%（n=6）。结论：该方法测定快速、重现性好,可用于八味獐牙菜丸的质量控制。